Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
about
Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia.Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs.MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.
P2860
Q30848149-8A9663B1-0876-4E20-835B-399F10B5563DQ34029221-130CFE4E-3C29-4077-87C9-55955A098763Q35778422-9DCE58A9-A6E8-432F-BEA5-D976DB6788BDQ37317385-E19DAFFC-5F50-4286-98E1-2D15C4889662Q37701084-0E74F355-EEAA-4AA7-89AD-D8C653D3D4E1Q39001266-8C1D33F1-6579-49D4-AE5A-142C449ACFF8Q39062888-5F64F03B-900F-4751-8932-88CF517BC127Q47618731-0610CCBB-AB26-4BFC-B888-513B7BFF57E0Q47804377-AAE7AA57-135C-4C71-B98A-0852C96D0934
P2860
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Bortezomib mitigates adverse p ...... d/refractory multiple myeloma.
@en
Bortezomib mitigates adverse p ...... d/refractory multiple myeloma.
@nl
type
label
Bortezomib mitigates adverse p ...... d/refractory multiple myeloma.
@en
Bortezomib mitigates adverse p ...... d/refractory multiple myeloma.
@nl
prefLabel
Bortezomib mitigates adverse p ...... d/refractory multiple myeloma.
@en
Bortezomib mitigates adverse p ...... d/refractory multiple myeloma.
@nl
P2093
P2860
P1433
P1476
Bortezomib mitigates adverse p ...... d/refractory multiple myeloma.
@en
P2093
Aisha Masood
Asher Chanan-Khan
Barb Bryant
Dan P Gaile
Dongliang Wang
George Mulligan
Gregory E Wilding
Jeff Miecznikowski
Kelvin P Lee
Leighton Stein
P2860
P304
P356
10.3109/10428194.2011.637212
P577
2011-12-06T00:00:00Z